**Abstract**

**Background:** *Homer1a* is an immediate-early-gene of the glutamatergic post-synaptic density (PSD), involved in synaptic plasticity and whose expression is elicited by antipsychotics (APDs). Here we provide a comparative analysis of *Homer1a* expression data by multiple first and second-generation APDs, in order to classify their impact on PSD and correlate it to their receptor profile.

**Methods:** we collected data from multiple *In Situ* Hybridization experiments carried out in our laboratory in standard controlled conditions, analysing *Homer1a* induction by APDs in Sprague-Dawley rat forebrain. *Homer1a* expression levels were normalized as the ratio of the corresponding mean vehicle value in each subregion. Normalized expression levels were quantitatively compared by ANOVA and Tukey's post-hoc test (p\<.05), and then grouped in four classes: no induction; light induction; moderate induction; high induction.

**Results:** In the cortex, *Homer1a* mRNA was not induced by sertindole, 4mg/kg ziprasidone, haloperidol (0.25 and 0.5mg/kg). Haloperidol 0.8mg/kg, 15mg/kg quetiapine, 10mg/kg and 35mg/kg amisulpride triggered light induction. Moderate induction was found for 30mg/kg quetiapine, olanzapine, clozapine, 10mg/kg ziprasidone and for asenapine at all doses tested. Notably, both clozapine and 10mg/kg ziprasidone induced the highest levels of *Homer1a* mRNA in the insular cortex.

In the striatum, sertindole did not induce *Homer1a* expression. Quetiapine and amisulpride were observed to trigger light induction of the gene. Clozapine triggered a light-moderate induction. Moderate induction was found by olanzapine and aripiprazole, while high induction was found by ziprasidone, asenapine, and haloperidol, especially in caudate-putamen regions.

A strong correlation with D2 receptor blockade and the extent of *Homer1a* expression in striatum, but not in the cortex, was found.

**Conclusions:** *Homer1a* expression levels throughout APDs were dose-dependent and under a major D2 receptor-dependent control. However, other molecular mechanisms (e.g. D1 receptor activation in striatum; 5-HT2A receptor blockade in the cortex) may contribute to affect its expression levels.
